Contact Us
Drug Search Results
More Filters [+]

Navafenterol

Alternative Names: navafenterol, azd-8871, azd8871, azd 8871
Latest Update: 2023-04-01
Latest Update Note: PubMed Publication

Product Description

MABA for chronic obstructive pulmonary disease (Sourced from: https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology.html)

Mechanisms of Action: MR Antagonist,ADRB2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Navafenterol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Obstructive Pulmonary Disease

Phase 1: Chronic Obstructive Pulmonary Disease|Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2018-001722-25

P2

Completed

Chronic Obstructive Pulmonary Disease

2019-08-07

D6640C00006

P2

Completed

Chronic Obstructive Pulmonary Disease

2019-08-07

32%
D6640C00005

P1

Completed

Chronic Obstructive Pulmonary Disease

2017-10-13

D6640C00004

P2

Completed

Chronic Obstructive Pulmonary Disease

2017-08-18

Recent News Events

Date

Type

Title

04/01/2023

PubMed

 Navafenterol for chronic obstructive pulmonary disease therapy.

01/06/2023

PubMed

 The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and beta(2) Adrenergic Receptor Agonist Navafenterol in Human Small Airways.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions